Filing Analysis
Harvard Bioscience, Inc. filed an 8-K to announce the release of its financial results for the three and six months ended June 30, 2026.
📋 Key Facts
- Financial results announced for the periods ending June 30, 2026 (three and six months).
- Press release issued on August 11, 2026, as Exhibit 99.1.
- Conference call scheduled for August 11, 2026, at 8:00 AM ET.
Harvard Bioscience, Inc. filed an 8-K to provide a corporate slide presentation as part of its routine investor relations activities. This filing is for informational purposes and does not contain material changes to business operations or financial standing.
📋 Key Facts
- Filed on August 11, 2026
- The company distributed an updated corporate slide presentation (Exhibit 99.1) to provide updates to the investment community.
- The filing is made under Item 7.01 (Regulation FD Disclosure).
- Signed by Mark Frost, Chief Financial Officer.
Harvard Bioscience reported the results of its 2026 Annual Meeting of Stockholders held on June 2, 2026. Stockholders approved the election of directors, the ratification of Grant Thornton LLP as auditors, executive compensation, and amendments to the 2021 Incentive Plan and Employee Stock Purchase Plan.
🚩 Red Flags
- Proposal 5 (Amended and Restated 2021 Incentive Plan) showed a relatively high number of 'Against' votes (680,030) compared to 'For' votes (1,131,261), indicating some shareholder dissent regarding equity dilution.
📋 Key Facts
- Stockholders approved the Amended and Restated 2021 Incentive Plan, increasing authorized shares for awards by 400,000 shares.
- As of December 31, 2025, 646,520 shares were available for future awards prior to this increase.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Two Class II Directors, John Duke and Katherine A. Eade, were elected for three-year terms.
- The amendment to the Employee Stock Purchase Plan (ESPP) was approved.
Harvard Bioscience, Inc. released an updated corporate slide presentation for May 2026 to be used in discussions with the investment community. The filing serves as a standard Regulation FD disclosure to provide business updates and summaries.
📋 Key Facts
- The filing was made under Item 7.01 (Regulation FD Disclosure) on May 12, 2026.
- Exhibit 99.1 contains the corporate slide presentation dated May 2026.
- The presentation is intended for distribution at various industry and investment conferences.
- The report was signed by Mark Frost, the Chief Financial Officer.
Harvard Bioscience, Inc. reported its financial results for the first quarter of 2026 on May 12, 2026. The company issued a press release and hosted a conference call to discuss the performance for the period ended March 31, 2026.
📋 Key Facts
- Financial results for the three months ended March 31, 2026, were released.
- A conference call was held on May 12, 2026, at 8:00 AM ET.
- The filing includes Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits).
- The information was furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Harvard Bioscience, Inc. filed a Current Report on Form 8-K to disclose an updated corporate slide presentation intended for use at upcoming industry and investor conferences in March 2026.
📋 Key Facts
- The filing was made under Item 7.01 (Regulation FD Disclosure).
- The corporate slide presentation is dated March 2026 and is attached as Exhibit 99.1.
- The presentation provides updates and summaries of the company's business for the investment community.
- The information is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
Harvard Bioscience, Inc. announced its financial results for the fourth quarter and full year ended December 31, 2025. The company hosted a conference call on March 12, 2026, to discuss the performance.
📋 Key Facts
- Announced financial results for the three and twelve months ended December 31, 2025
- Scheduled a conference call for March 12, 2026, at 8:00 AM ET
- The filing includes Exhibit 99.1, the press release detailing the financial results
Harvard Bioscience (HBIO) has formalized employment agreements for its CEO and newly permanent CFO, while confirming a 1:10 reverse stock split effective March 13, 2026. The CEO's new contract includes a $100,000 bonus contingent on the successful refinancing of the company's credit facility, suggesting recent financial restructuring.
🚩 Red Flags
- 1:10 reverse stock split effective March 13, 2026, typically indicating delisting risk or price maintenance issues.
- CEO bonus specifically tied to 'successful refinancing' of debt, highlighting recent liquidity or credit pressure.
- Significant post-split equity grants (75k and 30k units) may be highly dilutive given the company's micro-cap status.
📋 Key Facts
- CEO John Duke's base salary set at $515,000 with a $100,000 bonus for credit facility refinancing.
- Mark Frost appointed permanent CFO and Treasurer, effective March 6, 2026, with a $375,000 base salary.
- A 1:10 reverse stock split is confirmed for March 13, 2026.
- CEO and CFO target equity grants for 2026 are 75,000 and 30,000 RSUs respectively (post-split).
Harvard Bioscience stockholders approved a reverse stock split at a special meeting on March 6, 2026. The Board of Directors subsequently set a final ratio of 1-for-10, effective March 13, 2026, to reduce the outstanding share count.
🚩 Red Flags
- Reverse stock split (1-for-10 ratio) is a red flag escalator.
- Authorized shares remain at 80,000,000 despite the 90% reduction in outstanding shares, significantly increasing the potential for future dilution.
📋 Key Facts
- Stockholders approved a reverse split ratio range of 1-for-5 to 1-for-15.
- The Board finalized the ratio at 1-for-10.
- The split is effective at 4:30 p.m. ET on March 13, 2026.
- Outstanding shares will be reduced from approximately 44,179,894 to approximately 4,471,989.
- Authorized shares will remain at 80,000,000.
- Split-adjusted trading begins on March 16, 2026, under the existing symbol HBIO with a new CUSIP.
Harvard Bioscience, Inc. issued a press release containing preliminary unaudited financial results for the fourth quarter ended December 31, 2025.
📋 Key Facts
- Report date: February 10, 2026
- Subject: Preliminary Q4 2025 financial results (unaudited)
- The company notes that actual results may differ upon completion of year-end closing and auditing procedures.
- Interim CFO Mark Frost signed the report.
Harvard Bioscience has announced 'Project Viking,' a strategic restructuring plan to consolidate manufacturing operations. This involves closing its Holliston, MA facility and relocating production to Minneapolis, MN, Germany, Sweden, and the UK to improve efficiency.
🚩 Red Flags
- Significant restructuring charges ($3.4M-$4.4M) which may impact near-term earnings.
- Workforce reconfiguration/layoffs implied by 'targeted reconfiguration of the Company’s workforce'.
📋 Key Facts
- Closure of manufacturing facility in Holliston, MA.
- U.S. production transitioning to a hub in Minneapolis, MN.
- Relocation of specific product lines to facilities in Germany, Sweden, and the UK.
- Expected pre-tax restructuring charges: $3.4 million to $4.4 million.
- Estimated non-cash asset write-off/accelerated depreciation: $0.6 million to $0.7 million.
- Projected cost savings: ~$3 million in 2027 and ~$4 million annually starting in 2028.
- Restructuring expected to be substantially complete by H1 2027.
Harvard Bioscience, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings from a majority of shares to one-third (1/3) of the voting shares.
🚩 Red Flags
- Lowering quorum requirements can sometimes be used by management to facilitate decisions or shareholder actions with lower participation, though it is a common corporate governance adjustment.
📋 Key Facts
- Board approved amendment on January 19, 2026.
- Quorum requirement reduced from a majority to one-third (1/3) of capital stock entitled to vote.
- Amendment is effective immediately upon adoption.
Harvard Bioscience, Inc. filed an 8-K to provide an Investor Update slide presentation under Regulation FD disclosure. The filing is a routine communication of business strategy and outlook intended for the investment community.
📋 Key Facts
- The company distributed an 'Investor Update' slide presentation dated January 12, 2026.
- Information provided is furnished pursuant to Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
- The filing includes a standard forward-looking statements disclaimer regarding business strategy and outlook.
Harvard Bioscience entered into a $40 million senior secured loan agreement with BroadOak Income Fund, L.P. to refinance existing debt and provide working capital. The deal includes highly dilutive components, including convertible term loans and significant warrants.
🚩 Red Flags
- Highly dilutive financing: $1.00 conversion price and $0.50 warrants represent significant potential dilution for existing shareholders.
- Expensive debt: Double-digit interest rates (up to 12.80%) indicate high cost of capital.
- Lender control: The lender has board nomination rights and the company must establish an advisory board including a lender appointee.
- Prepayment penalties: Includes an exit fee of 10% on prepaid amounts, making refinancing difficult.
📋 Key Facts
- Total new financing of $40 million via three term loans: Term A ($10M), Term B ($22.5M), and Term C ($7.5M).
- Term C Loan is a senior secured convertible term loan with a conversion price of $1.00 per share.
- Automatic conversion trigger for Term C Loan if stock price exceeds $1.50 for 30 consecutive trading days.
- Issuance of warrants to purchase 2,000,000 shares at an exercise price of $0.50 per share.
- Interest rates are high: 12.80% (first two years) and 12.50% thereafter, or Prime + 5.25%.
- The loan is secured by substantially all assets of the Company and its subsidiaries.
- BroadOak Income Fund, L.P. has the right to nominate one member to the Board; Mr. William A. Snider was appointed effective Dec 17, 2025.
Harvard Bioscience is currently negotiating the refinancing or repayment of its existing credit agreement with Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company. The company expects to finalize these terms during Q4 2025.
🚩 Red Flags
- Active negotiations for debt restructuring/refinancing can indicate liquidity management needs common in micro-cap companies facing capital constraints.
📋 Key Facts
- Ongoing discussions regarding the existing credit agreement dated December 22, 2020.
- Lenders include Citizens Bank, N.A., Wells Fargo Bank, N.A., and First-Citizens Bank & Trust Company.
- The company aims to complete refinancing or repayment by the end of Q4 2025.
Harvard Bioscience, Inc. filed an 8-K to announce the release of its financial results for the three and nine months ended September 30, 2025.
📋 Key Facts
- Report date: November 6, 2025
- Reporting period: Three and nine months ended September 30, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results.
- A conference call was scheduled for 8:00 AM ET on November 6, 2025.
Harvard Bioscience received a 180-day extension from Nasdaq to regain compliance with the $1.00 minimum bid price requirement. The company's stock will be transferred from the Nasdaq Global Market to the Nasdaq Capital Market effective October 3, 2025.
🚩 Red Flags
- Delisting notice/Non-compliance with minimum bid price requirement ($1.00).
- Potential for a reverse stock split to artificially inflate share price.
- Failure to meet Nasdaq listing standards for 30 consecutive business days as previously disclosed.
📋 Key Facts
- Received notification of a Second Compliance Period from Nasdaq Staff on October 2, 2025.
- Deadline to regain compliance with the $1.00 minimum bid price is March 30, 2026.
- Compliance requires the stock to close at $1.00 or more for 10 consecutive business days.
- Common stock will transfer from Nasdaq Global Market to Nasdaq Capital Market effective October 3, 2025.
- The company explicitly mentions considering a reverse stock split as an option to regain compliance.
Harvard Bioscience, Inc. announced the appointment of Stephen DeNelsky to its Board of Directors and Nominating & Governance Committee, effective September 5, 2025.
📋 Key Facts
- Stephen DeNelsky appointed as Class I director, term expiring at the 2028 annual meeting.
- DeNelsky will serve on the Nominating & Governance Committee.
- Compensation includes an approximate $135,000 value: 110,000 restricted stock units and a $91,000 annual cash retainer.
- DeNelsky is currently a Managing Director at Oaktree Capital Management.
Harvard Bioscience entered into a retention agreement with Interim CFO Mark Frost, offering a $100,000 cash bonus contingent upon the successful refinancing of company debt by March 15, 2026. This arrangement is designed to ensure leadership stability during critical liquidity negotiations.
🚩 Red Flags
- Contingent compensation tied specifically to debt refinancing suggests significant liquidity pressure or upcoming maturity walls.
- The use of an 'Interim' CFO implies ongoing leadership instability in the finance department.
- High-stakes incentive structure indicates that successful debt restructuring is a critical survival/operational milestone for the company.
📋 Key Facts
- Interim CFO Mark Frost entered into a Retention Letter Agreement on August 12, 2025.
- A $100,000 cash bonus is contingent upon the successful refinancing of existing term loan and senior revolving credit facility debt.
- The deadline for the required refinancing (the 'Retention Date') is March 15, 2026.
- The retention bonus replaces a previous $50,000 bonus outlined in an April 10, 2025 offer letter.
- Agreement includes severance-like protections including 5 months of base salary and COBRA premiums if terminated without cause.
Harvard Bioscience entered into a Sixth Amendment to its Credit Agreement to waive defaults related to refinancing milestones and financial covenant breaches. However, the company explicitly stated there is substantial doubt regarding its ability to continue as a going concern due to uncertain access to capital needed to repay debt by December 2025.
🚩 Red Flags
- Explicit 'substantial doubt' regarding the company's ability to continue as a going concern.
- Failure to meet existing financial covenants and refinancing milestones.
- Hard deadline for refinancing or repayment set for December 5, 2025.
- Increased cost of debt (SOFR + 700 bps).
- Uncertainty in accessing alternative sources of capital.
📋 Key Facts
- Entered into Sixth Amendment to Credit Agreement on August 8, 2025.
- Lenders waived defaults related to refinancing milestones and net leverage/fixed charge coverage ratio covenants as of June 30, 2025.
- Financial covenants will not be tested for the fiscal quarter ended September 30, 2025, provided minimum liquidity of $3.0 million is maintained.
- Interest rate margin increased to SOFR + 700 bps.
- Company must take steps toward refinancing or repayment by December 5, 2025; failure constitutes an event of default.
- Amendment fee of $0.4 million (1.00% of outstanding debt) incurred.
Harvard Bioscience, Inc. filed an 8-K to announce the release of its financial results for the three and six months ended June 30, 2025.
📋 Key Facts
- Company issued a press release regarding financial results for the periods ending June 30, 2025.
- The announcement included details for a conference call held on August 11, 2025, at 8:00 AM ET.
- Interim CFO Mark Frost signed the report.
Harvard Bioscience announced the resignation of President and CEO James W. Green, effective August 15, 2025. The company has appointed John Duke as the new CEO, effective July 28, 2025, alongside several new board appointments.
🚩 Red Flags
- Leadership transition: Sudden departure of the CEO/Chairman, though stated as non-dispute related.
- Significant equity dilution potential via large RSU grants (1 million total units for new CEO).
📋 Key Facts
- James W. Green is resigning as President, CEO, and Chairman of the Board; resignation is not due to any disagreement or financial policy concerns.
- John Duke appointed as President and CEO effective July 28, 2025; he previously served as CEO of Plastic Molding Technology and held leadership roles at Corning Incorporated.
- New board members Robert Gagnon (Audit/Compensation Committee Chair) and Seth Benson (Audit Committee member) have been elected.
- CEO John Duke's compensation includes a $480,000 base salary and an anticipated 2026 equity target of $1,036,000.
- Duke received an initial grant of 500,000 RSUs (vesting over 3 years) and 500,000 market-condition RSUs linked to relative TSR vs. Russell 2000.
Harvard Bioscience, Inc. is in violation of Nasdaq's Audit Committee Composition Requirement following the resignation of Board member Alan Edrick on June 10, 2025. The company has received formal notification from Nasdaq Staff confirming non-compliance and is working to appoint a new independent director to regain compliance.
🚩 Red Flags
- Delisting notice/non-compliance with Nasdaq listing rules.
- Audit committee composition failure due to sudden director resignation.
- Regulatory scrutiny from Nasdaq Listing Qualifications Department.
📋 Key Facts
- Alan Edrick resigned from the Board and Audit Committee effective June 10, 2025.
- The resignation left only two members on the Audit Committee, violating Nasdaq Listing Rule 5605(c)(2)(A).
- Nasdaq Staff issued a formal letter on June 26, 2025, confirming non-compliance.
- The company intends to rely on a cure period under Nasdaq Listing Rule 5605(c)(4).
- Compliance must be restored by the earlier of the next annual meeting of stockholders or June 10, 2026.
Harvard Bioscience notified Nasdaq that it is non-compliant with the Audit Committee Composition Requirement following the resignation of Board member Alan Edrick on June 10, 2025. The company currently has only two members on its audit committee and intends to appoint a new independent director to regain compliance.
🚩 Red Flags
- Delisting notice regarding audit committee composition.
- Board vacancy resulting in regulatory non-compliance with exchange listing rules.
📋 Key Facts
- Company notified Nasdaq on June 18, 2025, of non-compliance with Nasdaq Listing Rule 5605(c)(2)(A).
- The deficiency is due to the resignation of Alan Edrick from the Board and Audit Committee effective June 10, 2025.
- The company currently has only two members on its audit committee.
- The company intends to rely on a cure period under Nasdaq Listing Rule 5605(c)(4).
- Compliance must be restored by the earlier of the next annual meeting of stockholders or June 10, 2026.
Harvard Bioscience, Inc. announced the resignation of Alan Edrick from its Board of Directors, effective June 10, 2025.
📋 Key Facts
- Alan Edrick resigned from the Board of Directors on June 10, 2025.
- The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Harvard Bioscience reported the results of its 2025 Annual Meeting of Stockholders, which included the election of directors and ratification of auditors. The filing also notes several board changes, including one resignation and two new appointments.
🚩 Red Flags
- Increase in authorized shares available for incentive plan (potential dilution, though standard for growth/retention).
📋 Key Facts
- Thomas Loewald resigned from the Board effective May 30, 2025; no disagreement reported.
- Stockholders approved an increase to the Amended and Restated 2021 Incentive Plan, adding 3,923,000 shares to the pool available for awards.
- John D. Duke appointed to the Board as a Class II director and member of Audit and Nominating/Governance Committees.
- Katherine Eade appointed as Lead Independent Director.
- Stockholders ratified Grant Thornton LLP as independent auditors for fiscal year 2025.
- James Green elected as Class I Director for a three-year term.
Harvard Bioscience, Inc. filed an 8-K to announce the release of its financial results for the first quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 12, 2025
- Reporting period: Three months ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) regarding financial results and details for an associated conference call.
Harvard Bioscience announced that Lead Independent Director Bertrand Loy will not stand for re-election at the upcoming 2025 Annual Meeting. The departure is characterized as non-contentious, with no disagreements reported regarding company operations or policies.
🚩 Red Flags
- Loss of long-standing board member (served since 2014), which may impact board continuity/institutional knowledge.
📋 Key Facts
- Bertrand Loy will not stand for re-election at the Company’s 2025 Annual Meeting (effective upon election results).
- Mr. Loy currently serves as Lead Independent Director and is a member of the Audit Committee and Nominating and Governance Committee.
- The departure is not due to any disagreement with the Company's operations, policies, or practices.
- He will continue in his current roles until the 2025 Annual Meeting.
Harvard Bioscience received a Nasdaq deficiency notice for failing to maintain the $1.00 minimum bid price requirement. Additionally, the company announced the resignation of its CFO and the appointment of an interim replacement.
🚩 Red Flags
- Delisting notice: Failure to meet the Nasdaq minimum bid price requirement.
- Potential for reverse stock split: The filing notes a reverse split may be required to regain compliance if the deficiency is not cured by October 1, 2025.
- Officer departure: Resignation of the Chief Financial Officer (CFO) during a period of regulatory non-compliance.
📋 Key Facts
- Nasdaq issued a deficiency notice on April 4, 2025, regarding failure to meet the $1.00 minimum bid price requirement (Rule 5450(a)(1)).
- The company has until October 1, 2025, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.
- CFO Jennifer Cote resigned on April 7, 2025; her resignation is not due to any disagreement with the company or financial policies.
- Mark Frost has been appointed Interim CFO and Treasurer effective upon Ms. Cote's departure (expected by May 12, 2025).
- Interim CFO compensation includes a $320,000 annual salary and 100,000 time-based RSUs vesting in one year.
Harvard Bioscience, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2024.
📋 Key Facts
- Financial results announced for the periods ending December 31, 2024.
- The company held a conference call on March 12, 2025, at 8:00 AM ET to discuss the results.
- Results were released via press release (Exhibit 99.1).
Harvard Bioscience entered into a Fifth Amendment to its credit facility that includes a waiver for covenant non-compliance and establishes strict refinancing milestones due by June 30, 2025. The company explicitly stated there is substantial doubt regarding its ability to continue as a going concern if it cannot secure alternative capital or extend debt obligations by the end of June.
🚩 Red Flags
- Explicit 'substantial doubt' regarding the company's ability to continue as a going concern.
- Strict refinancing deadline of June 30, 2025; failure to meet this results in inability to pay debt and fund operations.
- Lenders have capped the revolving credit facility, limiting access to new liquidity.
- Increased cost of capital (SOFR + 400 bps) and accelerated amortization schedules.
- Uncertainty regarding ability to access alternative sources of capital.
📋 Key Facts
- Entered into Fifth Amendment to term loan and senior revolving credit facility on March 10, 2025.
- Lenders waived non-compliance with consolidated net leverage ratio covenant as of Dec 31, 2024.
- Revolving credit facility commitment is now capped at the current outstanding amount.
- Interest rate increased to SOFR + 400 bps; amortization payments changed from quarterly to monthly.
- Company paid $0.1 million in fees for the amendment.
- Refinancing must be completed by June 30, 2025, with specific milestones due between March 14 and June 13, 2025.
Harvard Bioscience, Inc. filed an 8-K to announce the release of its financial results for the third quarter ended September 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Q3 2024).
- Financial results were released via press release on November 7, 2024.
- A conference call was scheduled for 8:00 AM ET on the date of the filing.
Harvard Bioscience, Inc. filed an 8-K to announce the issuance of its quarterly financial results for the three months ended June 30, 2024. The filing serves as a formal notification that earnings data has been released via press release.
📋 Key Facts
- Report date: August 8, 2024
- Reporting period: Three months ended June 30, 2024
- The company issued a press release (Exhibit 99.1) containing financial results.
- A conference call was scheduled for August 8, 2024, at 10:00 AM ET to discuss the results.
Harvard Bioscience, Inc. held its 2024 Annual Meeting of Stockholders on May 14, 2024. The filing reports the voting results for the election of a director, ratification of the independent auditor, and advisory approval of executive compensation.
📋 Key Facts
- Held 2024 Annual Meeting of Stockholders on May 14, 2024.
- Alan Edrick was elected to the Class III Director position for a three-year term (ending 2027) with 19,722,574 votes in favor.
- Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2024.
- Non-binding advisory vote approved compensation of Named Executive Officers (NEOs) with 27,472,149 votes in favor.
Harvard Bioscience, Inc. filed an 8-K to announce its quarterly financial results for the three months ended March 31, 2024. The filing serves as a formal notice of the earnings release and accompanying conference call.
📋 Key Facts
- Company issued a press release regarding financial results for the period ending March 31, 2024.
- A conference call was scheduled for May 7, 2024, at 8:00 AM ET to discuss the results.
- The filing is an announcement of earnings (Item 2.02) and does not contain the full financial statements within the text itself, referring instead to Exhibit 99.1.
Harvard Bioscience entered into a Third Amendment to its existing Credit Agreement with Citizens Bank, N.A. and other lenders. The amendment modifies the definition of 'Consolidated EBITDA' to allow for specific add-backs related to Employee Retention Credits and escheatment audit expenses.
🚩 Red Flags
- The modification of EBITDA definitions (add-backs) can sometimes be used to mask underlying operational weakness, though here it appears tied to specific non-recurring items (tax credits and audits).
📋 Key Facts
- Third Amendment to Credit Agreement dated March 28, 2024.
- Modification allows Consolidated EBITDA to be increased by commission fees related to Employee Retention Credits (expected in FY2024).
- Modification allows Consolidated EBITDA to be increased by reserves/expenses for a Delaware escheatment audit (~$600,000) expected in Q2 2024.
- The company previously received $3.1 million in employee retention credits in Q1 2024 and expects another $3.1 million during FY2024.
- Expected commission fee for these credits is approximately $1 million.
Harvard Bioscience announced the approval of its 2024 annual cash incentive plan by the Compensation Committee. The plan includes target awards for the CEO and CFO based on achieving specific corporate financial objectives.
📋 Key Facts
- The Compensation Committee approved the 2024 annual cash incentive plan on March 21, 2024.
- CEO and CFO are eligible for target award amounts as a percentage of their 2024 base salaries.
- Incentive payouts range from 0% to 150% of the target amount based on pre-defined corporate financial objectives.
Harvard Bioscience, Inc. filed an 8-K to announce its financial results for the three and twelve months ended December 31, 2023.
📋 Key Facts
- The company issued a press release regarding financial results on March 7, 2024.
- Reporting period covers the three and twelve months ended December 31, 2023.
- A conference call was scheduled for 8:00 AM ET on March 7, 2024, to discuss the results.
Harvard Bioscience released an investor presentation providing preliminary, unaudited revenue estimates for the full year 2023. The company notes that these figures are subject to change pending final audit and closing procedures.
🚩 Red Flags
- Preliminary/unaudited nature of the reported financial estimates means final figures may differ significantly once audited.
📋 Key Facts
- Released an investor presentation dated January 5, 2024 (Exhibit 99.1).
- Provided preliminary, unaudited estimates of full year 2023 revenue.
- The financial information is subject to completion of normal financial close procedures and ongoing audit for the year ended December 31, 2023.